Kantarjian et al53 assessed the efficacy and security of dasatinib, as when compared with imatinib, for the first-line therapy of CML-CP. 5 hundred and nineteen individuals with newly diagnosed CML-CP were randomly assigned to receive dasatinib at a dose of one hundred mg the moment day by day (259 people) https://masonw853nsw6.boyblogguide.com/profile